Phagelux Inc:製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Phagelux Inc - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C11334
◆発行会社(調査会社):GlobalData
◆発行日:2018年11月
◆ページ数:22
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:中国
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Phagelux Inc (Phagelux) is an anti-infectives company that provides antibacterial products and solutions. The company uses phage lysis enzymes and biological agents for the treatment of antibiotic resistant bacteria and related diseases in human beings and crops. Its product portfolio includes AgriPhage-Cmm a biological control for bacterial canker disease on tomato, AgriPhage a biological control for bacterial spot and bacterial speck on tomatoes and peppers, and Lexia to treat shrimp induced pancreatic diseases in humans. Phagelux’s pipeline products include investigational candidates and AgriPhage Xcv and Pst, fire blight, AgriPhage-Cmm, AgriPage citrus, and seed coating in crops. The company conducts research on delivery systems, phages for feeds and medicines of animals, and lysins for human uses. It operates research and development centers and manufacturing facilities in the US and China. Phagelux is headquartered in Shanghai City, China.

Phagelux Inc – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Phagelux Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Phagelux Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Phagelux Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Phagelux Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Phagelux Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Phagelux Inc, Pharmaceuticals & Healthcare, Deal Details 10
Asset Purchase 10
Phagelux Acquires Certain Assets of Scithera Microbial Technologies 10
Phagelux to Acquire Assets of Biophage Pharma 11
Phagelux Acquires Biodegradable Polymer Delivery Systems from Iveria 12
Venture Financing 13
Phagelux Raises Funds Through Venture Financing 13
OmniLytics Raises US$0.2 Million In Venture Financing 14
Partnerships 15
Phagelux Enters into Agreement with Johnson & Johnson Consumer 15
Equity Offering 16
Phagelux Raises Funds through Private Placement 16
Phagelux to Raise up to USD10 Million in Private Placement of Shares 17
Asset Transactions 18
Phagelux Acquires Certain Assets of Scithera Microbial Technologies 18
Phagelux Inc – Key Competitors 19
Phagelux Inc – Key Employees 20
Phagelux Inc – Locations And Subsidiaries 21
Head Office 21
Other Locations & Subsidiaries 21
Appendix 22
Methodology 22
About GlobalData 22
Contact Us 22
Disclaimer 22

List of Tables
Phagelux Inc, Pharmaceuticals & Healthcare, Key Facts 2
Phagelux Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Phagelux Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Phagelux Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Phagelux Inc, Deals By Therapy Area, 2012 to YTD 2018 8
Phagelux Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Phagelux Acquires Certain Assets of Scithera Microbial Technologies 10
Phagelux to Acquire Assets of Biophage Pharma 11
Phagelux Acquires Biodegradable Polymer Delivery Systems from Iveria 12
Phagelux Raises Funds Through Venture Financing 13
OmniLytics Raises US$0.2 Million In Venture Financing 14
Phagelux Enters into Agreement with Johnson & Johnson Consumer 15
Phagelux Raises Funds through Private Placement 16
Phagelux to Raise up to USD10 Million in Private Placement of Shares 17
Phagelux Acquires Certain Assets of Scithera Microbial Technologies 18
Phagelux Inc, Key Competitors 19
Phagelux Inc, Key Employees 20
Phagelux Inc, Subsidiaries 21

List of Figures
Phagelux Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Phagelux Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Phagelux Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Phagelux Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Phagelux Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Phagelux Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Phagelux Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Phagelux Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

★海外企業調査レポート[Phagelux Inc:製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Humana Inc.:企業の戦略・SWOT・財務情報
    Humana Inc. - Strategy, SWOT and Corporate Finance Report Summary Humana Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate act …
  • TIM SpA (TIT):企業の財務・戦略的SWOT分析
    TIM SpA (TIT) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the pot …
  • Pharm-Olam International Ltd-製薬・医療分野:企業M&A・提携分析
    Summary Pharm-Olam International Ltd (Pharm-Olam) is a contract research organization (CRO) which offers clinical research services to the pharmaceutical, biotechnology and medical device industries. The organization's service offerings include medical writing, monitoring, regulatory and ethics subm …
  • Hamilton Thorne Ltd (HTL):企業の財務・戦略的SWOT分析
    Summary Hamilton Thorne Ltd (Hamilton Thorne) is a medical equipment company that offers precision laser devices and advanced image analysis systems. The company's products include clinical lasers, animal and research sperm analysis products, research lasers, clinical sperm analysis products, sperm …
  • Crescendo Biologics Ltd-製薬・医療分野:企業M&A・提携分析
    Summary Crescendo Biologics Ltd (Crescendo) is a biopharmaceutical company that manufactures antibody therapeutics based on a transgenic mouse platform. The company s pipeline includes humabody programs targeting oncology. It specializes in the antibody discoveries and development that include CAT, …
  • Guardian Media Group plc:企業の戦略・SWOT・財務情報
    Guardian Media Group plc - Strategy, SWOT and Corporate Finance Report Summary Guardian Media Group plc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service o …
  • Novelis Inc:企業の戦略・SWOT・財務分析
    Novelis Inc - Strategy, SWOT and Corporate Finance Report Summary Novelis Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate act …
  • Nectar Lifesciences Ltd (NECLIFE):企業の財務・戦略的SWOT分析
    Summary Nectar Lifesciences Ltd (NecLife) is a research driven pharmaceutical company that manufactures active pharmaceutical ingredients (APIs). The company provides contract research and manufacturing services such as process development and optimization, process scale up and validation, multi kil …
  • Acer Inc (2353):企業の財務・戦略的SWOT分析
    Acer Inc (2353) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the p …
  • Pharming Group NV (PHARM):製薬・医療:M&Aディール及び事業提携情報
    Summary Pharming Group NV (Pharming) is a specialty pharmaceutical company which develops nutritional products for the treatment of genetic diseases and unmet medical needs. The company’s flagship product, Ruconest (Rhucin in non-European territories) is a recombinant human C1 inhibitor approved for …
  • 23andMe Inc-医療機器分野:企業M&A・提携分析
    Summary 23andMe Inc (23andMe) is a biotechnology research and information provider that offers tools for health and ancestry care. The company offers raw genetic data and ancestry-related genetic reports. It offers clinical development, research and development, ancestry services, commercialization …
  • Vital Images Inc:企業の戦略的SWOT分析
    Vital Images Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and servi …
  • Laing O’Rourke Plc:企業の戦略的SWOT分析
    Laing O'Rourke Plc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and ser …
  • Xilinx, Inc.:企業の戦略・SWOT・財務情報
    Xilinx, Inc. - Strategy, SWOT and Corporate Finance Report Summary Xilinx, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate a …
  • Kraftwerke Oberhasli AG:企業の戦略的SWOT分析
    Kraftwerke Oberhasli AG - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products an …
  • Zhejiang Jolly Pharmaceutical Co Ltd (300181):製薬・医療:M&Aディール及び事業提携情報
    Summary Zhejiang Jolly Pharmaceutical Co Ltd (Zhejiang Jolly Pharma) is a producer and marketer of pharmaceutical products. The company offers products in the form of tablets, capsules, granules, injections, dry powders, and others. Its products include Wuling powder, pseudomonas moth powder, cordyc …
  • MolMed SpA (MLM):企業の財務・戦略的SWOT分析
    Summary MolMed SpA (Molmed) is a biotechnology company which offers research, development, manufacturing and clinical validation of novel anticancer therapies. Its pipeline antitumour products include Zalmoxis (TK), a cell based therapy enabling bone marrow transplants donors for the treatment of hi …
  • Gibson Energy Inc (GEI)-石油・ガス分野:企業M&A・提携分析
    Summary Gibson Energy Inc. (Gibson) is an independent midstream energy company that provides integrated services to the oil and gas industry. The company transport, store, blend, process, market and distribute crude oil, condensate, natural gas liquids (NGLs), water, oilfield waste, and refined prod …
  • The New York Times Company (NYT):企業の財務・戦略的SWOT分析
    The New York Times Company (NYT) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and wea …
  • NV Bekaert SA:戦略・SWOT・企業財務分析
    NV Bekaert SA - Strategy, SWOT and Corporate Finance Report Summary NV Bekaert SA - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆